EditorialIs a decline in estimated GFR an appropriate surrogate end point for renoprotection drug trials?
Under an Elsevier user license
open archive
Cited by (0)
The authors declared no competing interests.
Copyright © 2014 International Society of Nephrology. Published by Elsevier Inc. All rights reserved.